Financial Ratios

JUBILANT PHARMOVA LTD.

NSE : JUBLPHARMABSE : 530019ISIN CODE : INE700A01033Industry : Pharmaceuticals & DrugsHouse : Jubilant Bhartia
BSE896.30-16.4 (-1.8 %)
PREV CLOSE ( ) 912.70
OPEN PRICE ( ) 912.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3394
TODAY'S LOW / HIGH ( )888.30 913.00
52 WK LOW / HIGH ( )823.7 1250
NSE894.45-18.55 (-2.03 %)
PREV CLOSE( ) 913.00
OPEN PRICE ( ) 909.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 894.45 (729)
VOLUME 121973
TODAY'S LOW / HIGH( ) 886.00 914.60
52 WK LOW / HIGH ( )802 1248
Select year
ParticularsMar2025Mar2024Mar2023Mar2022Mar2021
Operational & Financial Ratios
   Earnings Per Share (Rs)1.211.993.145.0513.47
   CEPS(Rs)4.555.035.867.3719.74
   DPS(Rs)5.005.005.005.005.00
   Book NAV/Share(Rs)144.98148.57151.61153.1080.52
   Tax Rate(%)48.9424.2237.074.9921.49
Margin Ratios
   Core EBITDA Margin(%)4.302.100.380.8915.76
   EBIT Margin(%)9.049.1212.0713.1913.84
   Pre Tax Margin(%)5.045.319.7911.6710.08
   PAT Margin (%)2.574.036.1611.097.92
   Cash Profit Margin (%)9.7010.1811.4916.1811.61
Performance Ratios
   ROA(%)0.651.061.713.425.89
   ROE(%)0.821.322.064.3311.03
   ROCE(%)2.522.643.674.3611.82
   Asset Turnover(x)0.250.260.280.310.74
   Sales/Fixed Asset(x)0.730.800.891.432.22
   Working Capital/Sales(x)4.293.483.722.65-50.26
Efficiency Ratios
   Fixed Capital/Sales(x)1.371.251.120.700.45
   Receivable days98.0289.0171.9165.740.00
   Inventory Days118.28131.29143.45162.540.00
   Payable days200.63160.53142.1195.8179.84
Valuation Parameters
   PER(x)739.30286.0588.9276.7450.53
   PCE(x)196.32113.1347.6652.6134.47
   Price/Book(x)6.163.831.842.538.45
   Yield(%)0.560.881.791.290.73
   EV/Net Sales(x)19.4311.915.848.724.17
   EV/Core EBITDA(x)110.0077.9533.5347.7223.77
   EV/EBIT(x)214.95130.5348.3466.1230.11
   EV/CE(x)5.523.441.742.216.12
   M Cap / Sales19.0311.525.488.514.00
Growth Ratio
   Net Sales Growth(%)-4.97-3.1411.62-73.22-13.71
   Core EBITDA Growth(%)9.84-14.966.32-72.08-12.72
   EBIT Growth(%)-5.87-26.792.19-74.48-13.81
   PAT Growth(%)-39.24-36.67-38.01-62.47-33.21
   EPS Growth(%)-39.24-36.67-37.90-62.47-33.21
Financial Stability Ratios
   Total Debt/Equity(x)0.130.150.130.070.38
   Current Ratio(x)1.561.711.602.080.55
   Quick Ratio(x)0.810.920.730.800.55
   Interest Cover(x)2.262.395.298.713.68
   Total Debt/Mcap(x)0.020.040.070.030.05

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.